Lexicon Pharmaceuticals, Inc. (LXRX)
| Market Cap | 734.18M +38.4% |
| Revenue (ttm) | 41.47M -29.0% |
| Net Income | -61.12M |
| EPS | -0.16 |
| Shares Out | 444.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,433,567 |
| Open | 1.630 |
| Previous Close | 1.600 |
| Day's Range | 1.620 - 1.675 |
| 52-Week Range | 1.100 - 2.680 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 4.55 (+175.76%) |
| Est. Earnings | Nov 5, 2026 |
About LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart fail... [Read more]
Financial Performance
In 2025, Lexicon Pharmaceuticals's revenue was $49.80 million, an increase of 60.24% compared to the previous year's $31.08 million. Losses were -$50.34 million, -74.88% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for LXRX stock is "Buy." The 12-month stock price target is $4.55, which is an increase of 175.76% from the latest price.
News
Lexicon initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Lexicon (LXRX) with an Overweight rating and $8 price target The firm’s thesis centers on confidence that sotagliflozin’s fully enrolled...
Lexicon initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Lexicon (LXRX) with an Overweight rating and $8 price target
Lexicon Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company is advancing late-stage programs for sotagliflozin in HCM and type 1 diabetes, with key trials fully enrolled and top-line data expected in Q1 2027. Partnerships, milestone payments, and pre-commercialization activities are accelerating, positioning the pipeline for major regulatory and commercial milestones.
Lexicon Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Focused on cardiometabolic diseases, the company is advancing sotagliflozin in HCM with phase III data expected in Q1, supported by a pragmatic trial design and strong FDA alignment. Regulatory progress in type 1 diabetes and strategic partnerships in obesity and neuropathic pain enhance growth prospects.
Lexicon Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026
The summit highlighted upcoming SONATA-HCM phase III data in Q1 2027, with strong commercial focus on HCM and T1D. Regulatory progress includes meeting FDA requirements for SOTA in T1D, with resubmission planned for Q4. Partnerships and AI initiatives aim to maximize pipeline value.
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences taking...
Lexicon announces results from post hoc analysis of SOLOIST-WHF trial
Lexicon (LXRX) announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure…
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure
Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851
Lexicon (LXRX) announced that it has earned a third $10M milestone payment in 2026 from Novo Nordisk (NVO) following the achievement of a patient dosing milestone in the ongoing Phase…
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders
Lexicon reports Q2 EPS (7c), consensus (5c)
Reports Q2 revenue $680,000, consensus $4M. “Lexicon (LXRX) continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to…
Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2026
Enrollment in the SONATA-HCM phase III trial was completed with over-enrollment, and top-line data are expected in Q1 2027. ZYNQUISTA's NDA resubmission is planned for Q4 2026, pending final STENO-1 data. Financial flexibility improved with a new debt facility and strong cash position.
Lexicon Pharmaceuticals Earnings release: Q2 2026
Lexicon Pharmaceuticals released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Lexicon Pharmaceuticals Slides: Q2 2026
Lexicon Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Lexicon Pharmaceuticals Quarterly report: Q2 2026
Lexicon Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 6, 2026.
Lexicon Pharmaceuticals Registration statement: Registration filing
Lexicon Pharmaceuticals filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA ® in type 1 diabetes nearing completion Phase 1 clinical development of LX985...
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, Aug...
Lexicon completes enrollment in SONATA-HCM study
Lexicon (LXRX) announced that randomization of patients has been completed in the pivotal Phase 3 “SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopath...
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXR...
Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a focused cardiometabolic pipeline, with key milestones including imminent completion of a pivotal HCM trial, FDA resubmission for type 1 diabetes, and strategic partnerships for obesity and pain assets. Unique clinical positioning and strong financial planning support future launches.
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups Presentations highlight consistent A1c reductio...
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Gl...
Lexicon Pharmaceuticals Slides: Investor presentation
Lexicon Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Lexicon Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
The conference highlighted late-stage and early-stage pipeline progress, including sotagliflozin’s regulatory path in Type 1 Diabetes and HCM, a strong financial position with recent capital raises, and strategic partnerships such as with Novo Nordisk for LX9851. Key milestones are expected through Q1 2027.